| Navneet Gupta, MD | |
|
213 E Butler Road, Suite F1, Mauldin, SC 29662-2172 | |
| (864) 284-0470 | |
| (864) 284-0471 |
| Full Name | Navneet Gupta |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 23 Years |
| Location | 213 E Butler Road, Mauldin, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962495531 | NPI | - | NPPES |
| 273064 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 41890 (Tennessee) | Secondary |
| 208100000X | Physical Medicine & Rehabilitation | 27306 (South Carolina) | Primary |
| Entity Name | Center For Rehabilitation And Pain Management, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033432778 PECOS PAC ID: 0749319739 Enrollment ID: O20100601000568 |
News Archive
Appature Inc., a leading provider of relationship marketing software, has been listed as a 2011 "Cool Vendor" in Life Sciences by leading analyst firm, Gartner, Inc.
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.
New research hopes to explain premature births and failed inductions of labour. The study by academics at the University of Bristol suggests a new mechanism by which the level of myosin phosphorylation is regulated in the pregnant uterus.
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Navneet Gupta, MD 213 E Butler Rd Ste F1, Mauldin, SC 29662-2172 Ph: (864) 284-0470 | Navneet Gupta, MD 213 E Butler Road, Suite F1, Mauldin, SC 29662-2172 Ph: (864) 284-0470 |
News Archive
Appature Inc., a leading provider of relationship marketing software, has been listed as a 2011 "Cool Vendor" in Life Sciences by leading analyst firm, Gartner, Inc.
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.
New research hopes to explain premature births and failed inductions of labour. The study by academics at the University of Bristol suggests a new mechanism by which the level of myosin phosphorylation is regulated in the pregnant uterus.
A new rule will require hospitals to report infections the follow a patient's treatment in intensive-care units. Meanwhile, a new study finds mortality risks related to dialysis are higher at for-profit chains.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.
› Verified 4 days ago